0 149

Cited 10 times in

Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion

Authors
 Min Kim  ;  Dong Hyun Lee  ;  Suk Ho Byeon  ;  Hyoung Jun Koh  ;  Sung Soo Kim  ;  Sung Chul Lee 
Citation
 BRITISH JOURNAL OF OPHTHALMOLOGY, Vol.99(9) : 1271-1276, 2015 
Journal Title
 BRITISH JOURNAL OF OPHTHALMOLOGY 
ISSN
 0007-1161 
Issue Date
2015
MeSH
Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage* ; Anti-Inflammatory Agents/administration & dosage* ; Antibodies, Monoclonal, Humanized/administration & dosage* ; Bevacizumab ; Dexamethasone/administration & dosage* ; Drug Implants ; Female ; Glucocorticoids/administration & dosage* ; Humans ; Intravitreal Injections ; Macular Edema/drug therapy* ; Male ; Middle Aged ; Retinal Vein Occlusion/drug therapy* ; Retrospective Studies ; Tomography, Optical Coherence ; Visual Acuity
Keywords
Macula ; Pharmacology ; Retina ; Treatment Medical
Abstract
BACKGROUND/AIMS: To compare the functional and anatomical outcomes of intravitreal bevacizumab (IVB) with those of dexamethasone implant injection (IVD) for macular oedema associated with branch retinal vein occlusion (BRVO). METHODS: Seventy-two patients with centre-involving macular oedema secondary to BRVO were retrospectively enrolled in the study; these patients were treated with either 1.25 mg IVB (44 eyes; mean injections: 2.92±1.38) pro re nata (PRN) by follow-up monthly or 700 µg IVD (28 eyes; mean injections: 1.71±0.47) given at 6-month intervals PRN and were followed for at least 12 months. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central foveal thickness (CFT). RESULTS: There was no statistically significant difference of mean change of the logarithm of the minimum angle of resolution BCVA between IVB and IVD groups at monthly visits, up to 12 months (all p>0.05); however, there was a trend towards greater BCVA gain in the IVB group than in the IVD group at 6 months (p=0.053). Additionally, 52.6% in the IVB group and 50% in the IVD group gained two or more lines of Snellen visual acuity at 12 months (p=0.85). The mean CFT decreased by 160 µm for the IVB group and by 140.7 µm for the IVD group at 12 months. Both the IVB group and the IVD group achieved statistically similar improvement of CFT at monthly visits, up to 5 months (all p>0.05); however, the CFT began to deteriorate after 5 months in the IVD group, and at 6 months, improvement in the IVB group was significantly greater than that in the IVD group (p=0.007). After a second IVD injection at 6 months, the IVD group showed significant improvement of CFT, and there was no significant difference of CFT change between the IVB and IVD groups until 12 months. CONCLUSIONS: For macular oedema secondary to BRVO, IVB administered PRN monthly and IVD administered PRN at 6-month intervals, yielded functionally and anatomically comparable outcomes at 12 months.
Full Text
http://bjo.bmj.com/content/99/9/1271
DOI
10.1136/bjophthalmol-2014-306236
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
Kim, Min(김민) ORCID logo https://orcid.org/0000-0003-1873-6959
Kim, Sung Soo(김성수) ORCID logo https://orcid.org/0000-0002-0574-7993
Byeon, Suk Ho(변석호) ORCID logo https://orcid.org/0000-0001-8101-0830
Lee, Dong Hyun(이동현)
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/156854
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse